Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068462 | 0.85 | LMNA (0.51) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL7223573 | 0.78 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL4743571 | 0.78 | ALDH1A1 (0.61) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL3450835 | 0.77 | MAOB (0.54) | LMNAMAOAMAPTRAB9ANPC1 | |
| SCHEMBL3450486 | 0.76 | MEN1 (0.47) | LMNACYP1A2MAPTRAB9ANPC1 | |
| SCHEMBL7705962 | 0.76 | CYP1A2 (0.60) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL7232286 | 0.74 | CYP1A2 (0.54) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL16701675 | 0.74 | RAB9A (0.56) | LMNACYP1A2MAPTRAB9ANPC1 | |
| SCHEMBL16351874 | 0.74 | CA1 (0.73) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL1965326 | 0.74 | CA1 (0.73) | LMNACYP1A2CYP3A4MAOACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087614-B2 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | PDE7A, PDE7B, PDE3A | LMNA 3150/4885CYP1A2 1294/4885CYP3A4 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.